Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + etoposide
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A two-drug antineoplastic regimen combining the anti-HER2 monoclonal antibody trastuzumab with the topoisomerase II inhibitor etoposide. Trastuzumab targets ERBB2/HER2 to inhibit oncogenic signaling and mediate immune effector functions, while etoposide induces DNA double-strand breaks by stabilizing the topoisomerase II–DNA cleavable complex. The combination has been explored particularly in HER2-positive metastatic breast cancer, including oral etoposide schedules in heavily pretreated patients, and in ongoing clinical studies in combination backbones for HER2-positive disease.
- Brand names
- Herceptin
- Other names
- VP16-trastuzumabVP-16-trastuzumabVP 16-trastuzumabtrastuzumab plus etoposideoral etoposide plus trastuzumab
02
Targets
TOP2B (DNA topoisomerase II beta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on trastuzumab + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + etoposide.